Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas.
In all 63 patients were treated monthly with a combination of mitomycin, doxorubicin, and cisplatin, and 27 (43%) experienced objective regression of their advanced sarcomas during a 3-month trial. The observed regression rate is numerically higher than any previously observed at our institution.
Edmonson
J H
JH
Long
H J
HJ
Richardson
R L
RL
Creagan
E T
ET
Green
S J
SJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy; D018219:Histiocytoma, Benign Fibrous / Q000188:drug therapy; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy; D008080:Liposarcoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009455:Neurofibroma / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D012512:Sarcoma, Ewing / Q000188:drug therapy; D013584:Sarcoma, Synovial / Q000188:drug therapy
D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin